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Class B GPCRs can activate multiple signalling effectors with the potential to exhibit biased agonism in
response to ligand stimulation. Previously, we highlighted key TM domain polar amino acids that were
crucial for the function of the GLP-1 receptor, a key therapeutic target for diabetes and obesity. Using
a combination of mutagenesis, pharmacological characterisation, mathematical and computational
molecular modelling, this study identifies additional highly conserved polar residues located towards
the TM helical boundaries of Class B GPCRs that are important for GLP-1 receptor stability and/or control-
ling signalling specificity and biased agonism. This includes (i) three positively charged residues
(R3.30227, K4.64288, R5.40310) located at the extracellular boundaries of TMs 3, 4 and 5 that are predicted
in molecular models to stabilise extracellular loop 2, a crucial domain for ligand affinity and receptor acti-
vation; (ii) a predicted hydrogen bond network between residues located in TMs 2 (R2.46176), 6 (R6.37348)
and 7 (N7.61406 and E7.63408) at the cytoplasmic face of the receptor that is important for stabilising the
inactive receptor and directing signalling specificity, (iii) residues at the bottom of TM 5 (R5.56326) and
TM6 (K6.35346 and K6.40351) that are crucial for receptor activation and downstream signalling; (iv) resi-
dues predicted to be involved in stabilisation of TM4 (N2.52182 and Y3.52250) that also influence cell sig-
nalling. Collectively, this work expands our understanding of peptide-mediated signalling by the GLP-1
receptor.
 2016 The Authors. Published by Elsevier Inc. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
GPCRs mediate signal transduction across cell membranes in
response to a wide range of extracellular stimuli [43]. Understand-ing how these receptors function at the molecular level requires
knowledge of how agonist binding is converted to receptor activa-
tion and consequently stimulation of downstream signalling cas-
cades that can be both G protein-dependent and G protein-
independent [37]. GPCRs are dynamic proteins that can explore
multiple conformational states and with the advances in GPCR
structural biology, new insights into the structural basis of GPCR
activation have revealed the importance of inter-connected net-
works of residues for conformational transitions that allow agonist
bound receptors to activate intracellular signalling cascades
[29,40].
Sequence alignments of related membrane proteins suggest
that polar residues are under evolutionary pressure for conserva-
tion and hence maintain common structural and functional roles
[25,26]. In support of this, there are a number of highly conserved
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interactions associated with their activation [4,5,42]. Class B
GPCRs typically contain more conserved polar residues in their
transmembrane (TM) bundle than Class A GPCRs, which may be
reflective of the diversity of receptors/ligands found within the
Class A subfamily, however, it may also reflect the mode by which
Class B ligands bind and activate their receptors. Peptide ligands
associate primarily with the large extracellular N-terminal
domain of Class B GPCRs, but also need to interact with the TM
bundle to promote receptor activation [6,47,48,41]. Previously,
we revealed the importance of networks of conserved polar resi-
dues located in the TM bundle of Class B GPCRs for controlling
receptor activation and downstream signalling of the glucagon-
like peptide-1 receptor (GLP-1R) [64,66,68]. This receptor plays
an essential role in nutrient regulated insulin release, and has
emerged as a major target for therapeutic treatment of type 2
diabetes and obesity. The GLP-1R is pleiotropically coupled to
multiple signalling pathways with evidence for biased agonism
by the physiological ligand oxyntomodulin, clinically used peptide
mimetics and synthetic non-peptide ligands, relative to the
cognate agonist GLP-1 [33,65,67]. In our previous studies, we
identified conserved buried polar residues were not only impor-
tant in receptor activation, but that some of these residues were
also important for biased agonism at this receptor. The break-
through crystal structures of the inactive TM domain of two Class
B GPCRs (the glucagon receptor (GCGR) and the corticotrophin
releasing factor receptor-1 (CRF1R)) that were subsequently
published, largely supported the predictions and conclusions from
the molecular modelling in these studies, highlighting that these
conserved residues may form conserved hydrogen bond networks
that are important for activation transition of all members of this
class of GPCRs [22,49].
The high resolution TM domain structures have provided bet-
ter structural templates for Class B GPCR modelling and enabled
the generation of a homology model of the inactive state of the
GLP-1R TM bundle [64,68]. In addition to the hydrogen bond net-
works predicted in our previous model, the new model identified
another network of residues in the inactive GLP-1R. This was
formed between conserved Class B polar residues located within
TMs 2, 6 and 7 at the intracellular face of the receptor and was
also evident in the crystal structures of the GCGR and the CRF1R
[22,49]. In addition to participation in hydrogen bond networks,
polar side chains located within the TM bundle of GPCRs can
have other important functions. These include the formation of
interactions with ligands or effectors and their ability to snorkel
out towards phospholipid head groups, thereby stabilising TM
helices within the bilayer [51]. These functions of polar TM resi-
dues are often (although not always) limited to residues that
reside either towards the extracellular or intracellular TM bound-
aries. While our earlier studies on the GLP-1R focused on con-
served polar residues that our original model predicted to
reside in water-mediated hydrogen bond interaction networks,
or in the central region of the TM bundle forming helical packing
interactions, this current study explores the roles of the remain-
ing conserved Class B GPCR TM polar residues, which are pre-
dicted to reside close to the TM boundaries (Fig. 1). This set of
residues includes the amino acids located within the additional
hydrogen bond network at the intracellular face of Class B GPCRs.
We have assessed the role of these residues on GLP-1R function
using a combination of mutagenesis, molecular modelling and
pharmacological characterisation of multiple ligands for affinity
and activation of three signalling endpoints. This identified resi-
dues important for ligand affinity, receptor folding and those con-
tributing to biased agonism, expanding the current understanding
of the functional role of highly conserved polar residues within
Class B GPCRs.2. Materials and methods
2.1. Materials
Dulbecco’s modified Eagle’s medium (DMEM), hygromycin-B
and Fluo-4 acetoxymethyl (AM) ester were purchased from Invitro-
gen (Carlsbad, CA, USA). Foetal bovine serum (FBS) was purchased
from Thermo Fisher Scientific (Melbourne, VIC, Australia). The
QuikChangeTM site-directed mutagenesis kit was purchased from
Stratagene (La Jolla, CA, USA). AlphaScreenTM reagents, Bolton-
Hunter reagent [125I] and 384-well ProxiPlates were purchased
from PerkinElmer Life and Analytical Sciences (Waltham, MA,
USA). SureFireTM ERK1/2 reagents were generously supplied by
TGR Biosciences (Adelaide, SA, Australia). SigmaFast o-
phenylenediamine dihydrochloride (OPD) tablets and antibodies
were purchased from Sigma–Aldrich (St. Louis, MO, USA). GLP-1
peptides were purchased fromMimotopes (Clayton, VIC, Australia).
All other reagents were purchased from Sigma–Aldrich (St. Louis,
MO, USA) or BDH Merck (Melbourne, VIC, Australia) and were of
an analytical grade.
2.2. Residue numbering
Throughout, residues were numbered using the numbering sys-
tem described previously [66], whereby the most conserved resi-
due in each Class B GPCR TM domain was assigned 0.50 with this
number preceded by the TM number. Each residue is numbered
according to its relative position to the residue at 0.50 in each helix
and its absolute residue number is shown in superscript. The rela-
tive positions of the residues assessed in this study are shown in
Fig. 1B–D.
2.3. Receptor mutagenesis
To study the influence of polar TM amino acids on receptor
function, the desired mutations were introduced to an N-
terminally double c-myc labelled wildtype human GLP-1R in the
pEF5/FRT/V5-DEST destination vector (Invitrogen); this receptor
had equivalent pharmacology to the untagged human GLP-1R.
Mutagenesis was carried out using oligonucleotides for site-
directed mutagenesis purchased from GeneWorks (Hindmarsh,
SA, Australia) and the QuikChangeTM site-directed mutagenesis kit
(Stratagene). Sequences of receptor clones were confirmed by
automated sequencing at the Australian Genome Research Facility.
Mutated residues and their conservation across human Class B
peptide hormone receptors are illustrated in Fig. 1.
2.4. Transfections and cell culture
Wildtype and mutant human GLP-1R were isogenically inte-
grated into FlpIn-Chinese hamster ovary (FlpInCHO) cells (Invitro-
gen) and selection of receptor-expressing cells was achieved
through treatment with 600 lg ml1 hygromycin-B. Transfected
and parental FlpInCHO cells were maintained in DMEM supple-
mented with 10% heat-inactivated FBS and incubated in a humid-
ified environment at 37 C in 5% CO2. For all experiments cells
passages 8–20 were used.
2.4.1. Radioligand binding assay
FlpInCHO wildtype and mutant human GLP-1R cells were
seeded at a density of 3  104 cells/well into 96-well culture plates
and incubated overnight at 37 C in 5% CO2, and radioligand bind-
ing carried out as previously described [32]. Briefly, binding assays
were performed on whole cells incubated overnight at 4 C with
0.05 nM 125I-exendin-4(9–39) tracer and increasing concentrations
Fig. 1. Conservation and location of polar residues mutated in this study. (A) Conservation of polar residues mutated in this study across the human Class B GPCRs (the
secretin-like subclass). Residues absolutely conserved are highlighted in grey. These residues shown are conserved as polar (with the exception of 5.56 and 6.35 where one
receptor subtype is not) across all mammalian species of receptor cloned to date. GLP-1R; glucagon-like peptide-1 receptor, GLP-2R; GLP-2 receptor, GIP, gastric inhibitory
polypeptide receptor; GluR, glucagon receptor; PTH-1R, parathyroid hormone receptor 1; PTH-2R, PTH receptor 2; SecR, secretin receptor; CTR, calcitonin receptor; CLR,
calcitonin-like receptor; CRF1, corticotropin-releasing factor receptor 1; CRF2, corticotropin-releasing factor receptor 2; GHRHR, GH-releasing hormone receptor; VPAC1R,
vasoactive intestinal polypeptide type-1 receptor; VPAC2R, vasoactive intestinal polypeptide type-2 receptor, PACR, pituitary adenylate cyclase activating polypeptide 1
receptor. (B) Schematic representation of the TM domain of the human GLP-1R. The most conserved residue in each helix is highlighted as a square with a bold letter and
represent residue 0.50 for that helix. Residues mutated in the present study are shown in grey. (C) Three-dimensional molecular homology model of the inactive TM bundle of
the GLP-1R. (D) Three-dimensional molecular model of the TM bundle of the active full length model of the GLP-1R. The bound GLP-1 peptide is shown dipping into the
bundle (dark red helix) and the Gas peptide fragment bound at the intracellular face is shown in dark blue. In (C) and (D), side chains mutated in this study are highlighted in
space fill with dark green indicating positively charged residues located towards the extracellular face of the bundle and interact with ECL2; pale green, positively charged
residues located towards the intracellular face that may interact with lipid headgroups; red, residues in TMs 2, 6 and 7 that form a hydrogen bond network in the apo
receptor; purple, residues in TMs 2 and 3 that stabilise interactions with TM4. (For interpretation of the references to colour in this figure legend, the reader is referred to the
web version of this article.)
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NaOH and radioactivity determined by c-counting. For each cell
line in all experiments, total binding was defined by 0.05 nM
125I-exendin-4(9–39) alone, and nonspecific binding was defined
by co-incubation with 1 lM exendin-4(9–39). For analysis, data
are normalised to the specific binding for each individual
experiment.
2.5. cAMP accumulation assay
FlpInCHO wildtype and mutant human GLP-1R cells were
seeded at a density of 3  104 cells/well into 96-well culture plates
and incubated overnight at 37 C in 5% CO2. cAMP assays were car-
ried out as previously described [33]. Briefly, cells were incubated
with increasing concentrations of peptide ligands for 30 min at
37 C in the presence of IBMX. Cells were lysed and cAMP levelswere detected using a cAMP AlphaScreenTM detection kit (PerkinEl-
mer). All values were converted to concentration of cAMP using a
cAMP standard curve performed in parallel, and data were subse-
quently normalised to the response of 100 lM forskolin in each cell
line.
2.6. pERK1/2 assay
FlpInCHO wildtype and mutant human GLP-1R cells were
seeded at a density of 3  104 cells/well into 96-well culture plates
and incubated overnight at 37 C in 5% CO2. Ligand-mediated
pERK1/2was determined using the AlphaScreenTM ERK1/2 SureFireTM
protocol as previously described [39]. Briefly, cells were serum
starved for 6 h prior to assay. Initial pERK1/2 time course experi-
ments were performed over 1 h in the presence of either vehicle
or 1 lM peptide to determine the time at which agonist-mediated
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AlphaScreenTM ERK1/2 SureFireTM kit. Subsequent experiments were
then performed with increasing concentrations of peptides at the
time required to generate a maximal pERK1/2 response using
1 lM peptide. The kinetics of pERK1/2 response for each mutant
receptor was similar toWT, peaking at 6 min. Datawere normalised
to the maximal response elicited by 10% FBS in each cell line, deter-
mined at 6 min (peak FBS response).
2.7. iCa
2+ mobilisation assay
FlpInCHO wildtype and mutant human GLP-1R cells were
seeded at a density of 3  104 cells/well into 96-well culture plates
and incubated overnight at 37 C in 5% CO2, and receptor-mediated
iCa2+ mobilisation determined as previously described [61]. Briefly,
cells were incubated for 1 h with the cell-permeant Ca2+ fluo-
rophore, Fluo-4/AM (10 lM) in the presence of 2 mM probenecid
prior to determining peptide-mediated changes in fluorescence in
a Molecular Devices FlexStation (Molecular Devices, Palo Alto,
CA, USA). Fluorescence was determined immediately after peptide
addition, with an excitation wavelength set to 485 nm and an
emission wavelength set to 520 nm, and readings taken every
1.36 s for 120 s. Peak magnitude was calculated using five-point
smoothing, followed by correction against basal fluorescence. The
kinetics for ligand-mediated iCa2+ were not altered by any of the
mutations. The peak value was used to create concentration–re-
sponse curves. Data were normalised to the maximal response eli-
cited by 100 lM ATP.
2.8. Cell surface receptor expression
FlpInCHO wildtype and mutant human GLP-1R cells, with
receptor DNA previously incorporated with an N-terminal double
c-myc epitope label, were seeded at a density of 25  104 cells/well
into 24-well culture plates and incubated overnight at 37 C in 5%
CO2, washed three times in 1 PBS and fixed with 3.7%
paraformaldehyde (PFA) at 4 C for 15 min. Cell surface receptor
detection was then performed using a cell surface ELISA protocol
to detect the cMyc epitope tag located at the extracellular N-
terminus of the receptor, as previously described [32]. Data were
normalised to the basal fluorescence detected in FlpInCHO parental
cells. Specific 125I-exendin-4(9–39) binding at each receptor
mutant, as identification of functional receptors at the cell surface,
was also determined (corrected for nonspecific binding using 1 lM
exendin-4(9–39)) as described in [65].
2.9. Molecular modelling
Two GLP-1R models were used to aid interpretation of muta-
tional data; the methods for generation of these models have been
described previously [64]. Briefly, the molecular models were con-
structed in three stages. An NMR structural ensemble of a short,
conformationally constrained GLP-1 agonist (equivalent to GLP-1
(7–18), pdb code 2N0I [21], was docked into a preliminary TM
comparative model of GLP-1R, which was based on the glucagon
X-ray crystal structure (PDB code 4L6R, (Sui et al., 2013)), using
Glide (v6.9) SP peptide and the OPLS force field [56]. The conforma-
tionally constrained peptide was mutated to GLP-1 using PLOP
[27]. GLP-1(7–18) was structurally aligned with GLP-1(10–35)
co-crystallised with the ECD (PDB code 3IOL [58]), using VMD
[24]. Duplicated residues were selectively removed from the com-
plex, thus creating two overlapping templates that were key to
combining the TM and ECD domains. These templates and the rel-
evant portions of the X-ray structure of the b2-adrenergic receptor:
G protein complex [45] were used to generate 2000 full length
active GLP-1R (R27-R421) models containing the GLP-1(7–36)-NH2 peptide and the C-terminal peptide of the G protein (Gs)
(R374-L394) using the comparative modelling programme Model-
ler 9.16 [16]; the modelling was carried out in the presence of a set
of distance constraints as described in [64]. These structures are
available from ftp://ftp.essex.ac.uk/pub/oyster/Wootten_JBC_
2016/ (username ftp, password anonymous).
2.10. Molecular dynamics simulations
The GLP-1R model was inserted into a hydrated equilibrated pal
mitoyloleoylphosphatidylcholine (POPC) bilayer using the
CHARMM-GUI interface [28]. Potassium and chloride ions were
added to neutralise the system at an ionic strength of approxi-
mately 150 mM. Lipid14 (for POPC), AMBER99SP (for the protein)
and TIP3P water model parameters were added using ambertools
[7]. The simulations were carried out using ACEMD [19] on a
purpose-built metrocubo GPU workstation. The system was energy
minimised, heated from 0 K to 300 K in the NVT ensemble for
160 ps then simulated in the NPT ensemble, with 10 kcal mol1 -
A2 positional harmonic restraints applied to the protein heavy
atoms, which were progressively reduced to 0 over the course of
15 ns. Bond lengths to hydrogen atoms were constrained using
M-SHAKE [34]. Production simulations were performed in the
NPT ensemble at 300 K and 1 atm, using a Langevin thermostat
for temperature coupling and a Berendsen barostat for pressure
coupling. Non-bonded interactions were cutoff at 10.0 Å, and
long-range electrostatic interactions were computed using the par-
ticle mesh Ewald method (PME) with dimensions of 8686142
using a spacing of 1.00 Å. The unconstrained simulation was run
for 500 ns. Quantitative analysis of the trajectory was conducted
in VMD.
2.11. Data analysis
All data were analysed using Prism 6 (GraphPad Software Inc.,
San Diego, CA, USA). For all analyses the data are unweighted
and each y value (mean of replicates for each individual experi-
ment) is considered an individual point. To calculate IC50, EC50
and Emax values, concentration response signalling data were anal-
ysed as previously described [30] using a three-parameter logistic
equation. IC50 values obtained from binding studies were then cor-
rected for radioligand occupancy as previously described using the
radioligand affinity (Ki) experimentally determined for each
mutant.
To quantify efficacy in the system, all data were fitted with an
operational model of agonism to calculate estimated s values. s
is the operational measure of efficacy in the system, which incor-
porates signalling efficacy and receptor density. This model has
been extensively described previously [30,66,64]. All estimated s
values were then corrected to cell surface expression (sc) as deter-
mined by cell surface ELISA and errors propagated from both s and
cell surface expression.
Signalling bias was also quantified as previously described by
analysis of concentration–response curves with nonlinear regres-
sion using an operational model of agonism, but modified to
directly estimate the ratio of sc/KA [30,66,64]. All estimated sc/KA
ratios included propagation of error for both sc and KA. Changes
in sc/KA ratios with respect to wildtype of each mutant were used
to quantitate bias between signalling pathways. Accordingly, bias
factors included propagation of error from sc/KA ratios of each
pathway.
2.12. Statistics
Changes in peptide affinity, potency, efficacy, cell surface
expression and bias of each mutant receptor in comparison to
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analysis of variance and Dunnett’s post test, and significance was
accepted at p < 0.05.
3. Results
Sequence alignments of the human Class B receptor subtypes
reveal 22 conserved polar residues that are predicted to reside
either in the TM bundle or at the membrane interface (10 of which
are absolutely conserved as the same residue). An additional 2 resi-
dues are also very highly conserved in this subfamily (with the
exception of 1 receptor subtype for loci 6.35 and 3 receptor sub-
types for 5.56). We have previously reported the effects of muta-
tion of 13 of these residues in the GLP-1R [64,66]. In this study
we have probed the function of the remaining residues (Fig. 1A).
All of these are located at TM helical boundaries/interfaces with
loops, with the exception of Q7.65410 that is located intracellularly
within the predicted helix 8 (H8) at the bottom of TM7 (Fig. 1B–D).
Each residue was individually mutated to Ala, verified by DNA
sequencing and analysed for the effect of mutation on receptor
function.
Wildtype and mutant human GLP-1Rs were isogenically inte-
grated into FlpInCHO host cells by recombination that allows for
direct comparison of cell surface expression as there should not
be variations that arise due to differences in gene transcription.
Cell surface expression was assessed by both antibody detection
of the N-terminal double c-myc epitope label using ELISA and
whole cell binding using [125-I]-exendin-4(9–39) (Table 1). A num-
ber of mutations resulted in significantly altered cell surface
expression relative to the wildtype receptor, with consistent
expression changes observed using both methods. Whole cell equi-
librium competition binding studies were used to assess orthos-
teric peptide ligand affinities for the wildtype and each of the
mutant GLP-1Rs (Table 1). These were performed with the endoge-
nous agonists GLP-1(7–36)NH2 (GLP-1) and oxyntomodulin, in
addition to the exogenous agonist exendin-4 and an antagonist
exendin-4(9–39), all in competition with the radiolabelled ligand
125I-exendin-4(9–39). This revealed a number of mutations that
globally altered peptide affinity and those that had selective effects
of peptide affinity (Table 1).
Activation/strength of coupling to three cellular signalling cas-
cades (cAMP production, ERK1/2 phosphorylation (pERK1/2) and
intracellular calcium mobilisation (iCa2+)) was evaluated through
the generation of concentration–response curves for all receptorsTable 1
Effects of mutation on GLP-1R peptide ligand affinities and cell surface expression. Mut
determined by equilibrium competition binding using [125-I]-exendin-4(9–39). Ligand a
expressed as mean ± S.E.M of four to six independent experiments, conducted in duplicat
saturation binding, both normalised to the wildtype receptor. All data are expressed as me
in affinity or expression were analysed with one-way analysis of variance (compared to the
be experimentally defined.
Receptor construct Ligand binding affinity (pKi)
GLP-1(7–36)NH2 Oxyntomodulin E
Wildtype 8.67 ± 0.05 7.26 ± 0.04 8
R2.46176A 8.40 ± 0.07 7.28 ± 0.08 8
N2.52182A ND ND N
R3.30227A 7.41 ± 0.08⁄ 6.69 ± 0.12⁄ 7
Y3.53250A 8.49 ± 0.09 6.99 ± 0.24 8
K4.64288A 6.90 ± 0.08⁄ 6.29 ± 0.07⁄ 7
R5.40310A 7.45 ± 0.12⁄ 6.11 ± 0.08⁄ 7
R5.56326A 8.51 ± 0.09 7.22 ± 0.06 8
K6.35346A 9.20 ± 0.07⁄ 7.68 ± 0.05 9
R6.37348A 8.38 ± 0.08 7.21 ± 0.08 8
K6.40351A 8.39 ± 0.07 7.25 ± 0.14 8
E7.63408A 8.62 ± 0.12 7.34 ± 0.09 8
Q7.65410A 8.72 ± 0.09 7.22 ± 0.05 9with each peptide agonist (Figs. 2–4). In most cases, mutations that
resulted in changes in cell surface expression and/or affinity also
produced significant changes on EC50 and/or Emax values (Table 2).
A direct measure of efficacy via calculation of Logsc values allows
for direct comparison of receptor activation of individual intracel-
lular signalling pathways at the different receptor mutants com-
pared to the wildtype receptor, independently of their ligand
affinity and cell surface expression. These were determined by ana-
lysing all concentration–response curves using an operational
model of agonism to determine relative signalling efficacy esti-
mates (logs values) that were corrected to different receptor
expression levels by normalisation to what they would be if the
mutant receptor were expressed at the same level as the wildtype
(logsc values, Table 3). Cell surface expression data obtained from
antibody binding were used for this correction instead of the Bmax
from ligand binding studies, as one mutant showed no detectable
radioligand binding, however correction with Bmax yielded similar
efficacy values (data not shown). In addition, functional affinities
(LogKA) that describe the affinity of the receptor when coupled
to a given signalling pathway were also derived from the opera-
tional analysis (Table 4). The assessment of multiple signalling
pathways also provided the ability to measure the signal bias of
mutant receptors relative to the wildtype to obtain a quantitative
measure of the relative bias between two pathways (Table 5,
Fig. 5).
To aid in interpretation of the experimental data, we used our
two published GLP-1R models [64]; an inactive apo model of the
TM bundle only and a GLP-1R:GLP-1:Gas complex that was gener-
ated using multiple structural templates (Fig. 1C–D). The combined
results from expression, affinity and efficacy data (derived from the
concentration–response curves) are presented in detail in the con-
text of the predicted locations of mutated residues within these
molecular models, clustering those located close in 3D space.
3.1. Three conserved positively charged residues located at the
extracellular ends of TM helices 3, 4 and 5 are essential for high affinity
agonist binding and conformational transitions linked to pleiotropic
effector coupling through stabilisation of ECL2
Three highly conserved positively charged residues, R3.30227,
K4.64288 and R5.40310, located close to the extracellular surface
of the GLP-1R are predicted to form direct interactions with resi-
dues in ECL2 in the apo and peptide bound models (Fig. 6).
R3.30227 is predicted to interact within the proximal region ofant and WT GLP-1Rs were stably expressed in ChoFlpIn cells and agonist affinities
ffinities were determined using a three-parameter logistic equation and values are
e. Cell surface expression was measured by ELISA against the c-myc epitope and by
an ± S.E.M of four to six independent experiments, conducted in duplicate. Differences
wildtype receptor) and Dunnett’s post test (*p < 0.05). ND means data were unable to
Cell surface expression
xendin-4 Exendin-4(9–39) ELISA Bmax
.87 ± 0.04 8.11 ± 0.04 100 ± 1 100 ± 2
.61 ± 0.11 8.17 ± 0.08 66 ± 2⁄ 72 ± 1⁄
D ND 39 ± 5⁄ ND
.60 ± 0.09⁄ 8.52 ± 0.08⁄ 95 ± 4 83 ± 2
.68 ± 0.23 7.94 ± 0.06 82 ± 8 97 ± 4
.39 ± 0.05⁄ 8.16 ± 0.05 107 ± 3 116 ± 2
.99 ± 0.11⁄ 7.87 ± 0.14 40 ± 8⁄ 23 ± 3⁄
.59 ± 0.07 8.09 ± 0.08 112 ± 10 141 ± 3⁄
.34 ± 0.06⁄ 8.37 ± 0.04 175 ± 13⁄ 159 ± 5⁄
.80 ± 0.08 7.98 ± 0.08 57 ± 4⁄ 60 ± 1⁄
.92 ± 0.06 7.76 ± 0.08⁄ 81 ± 3 76 ± 2
.29 ± 0.11⁄ 8.12 ± 0.07 59 ± 5⁄ 45 ± 4⁄
.08 ± 0.09 8.39 ± 0.06 71 ± 5⁄ 78 ± 7
Fig. 2. cAMP concentration–response curves for polar TM boundary Ala mutants. Concentration–response curves for cAMP accumulation of wildtype and mutant receptors
stimulated by GLP-1 (A, B), exendin-4 (C, D) or oxyntomodulin (E, F) in CHOFlpIn cells stably expressing wildtype or mutant receptors. Data are normalised to the response
elicited by the wildtype receptor and analysed with an operational model agonism. All values are mean ± S.E.M of four to six independent experiments, conducted in
duplicate.
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bound model (Fig. 6). K4.64288 forms interactions at the opposite
end of ECL2, close to the top of TM5 in the apo receptor and forms
multiple interactions with ECL2 in the GLP-1 peptide bound model.In both inactive and active models, R5.40310 resides close to N300
that is also predicted to form a direct interaction with GLP-1.
R5.40310 also resides close to His7 of GLP-1 in the active model
where it may form a direct interaction (Fig. 6). MD simulations per-
Fig. 3. pERK1/2 concentration–response curves for polar TM boundary Ala mutants. Concentration–response curves or pERK of wildtype and mutant receptors stimulated by
GLP-1 (A, B), exendin-4 (C, D) or oxyntomodulin (E, F) in CHOFlpIn cells stably expressing wildtype or mutant receptors. Data are normalised to the response elicited by the
wildtype and analysed with an operational model agonism. All values are mean ± S.E.M of four to six independent experiments, conducted in duplicate.
74 D. Wootten et al. / Biochemical Pharmacology 118 (2016) 68–87formed on this static GLP-1 bound active model revealed that
R5.40310 forms transient hydrogen bond interactions with both
N300 in ECL2 and His7 of GLP-1 in the first 360 ns of the MD sim-ulation, however both of these interactions are lost towards the
end of the simulation with R5.40310 forming a direct interaction
with E6.53364 in TM6 (Fig. 7).
Fig. 4. iCa2+ mobilisation concentration–response curves for polar TM boundary Ala mutants. Concentration–response curves or iCa2+ mobilisation of wildtype and mutant
receptors stimulated by GLP-1 (A, B), exendin-4 (C, D) or oxyntomodulin (E, F) in CHOFlpIn cells stably expressing wildtype or mutant receptors. Data are normalised to the
response elicited by the wildtype and analysed with an operational model agonism. All values are mean ± S.E.M of four to six independent experiments, conducted in
duplicate.
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Table 2
Effects of mutation on GLP-1R peptide concentration response in cAMP, pERK1/2 and iCa2+ mobilisation. Mutant and WT GLP-1Rs were stably expressed in ChoFlpIn cells and
concentration–response curves were generated in each pathway for the three agonists. pEC50 and Emax values were determined using a three-parameter logistic equation and
values are expressed as mean ± S.E.M of four to six independent experiments, conducted in duplicate. Differences in pEC50 or Emax were analysed with one-way analysis of
variance (compared to the wildtype receptor) and Dunnett’s post test (*p < 0.05). ND means data were unable to be experimentally defined.
Signalling pathway Receptor construct GLP-1 Oxyntomodulin Exendin-4
pEC50 Emax (% WT) pEC50 Emax (% WT) pEC50 Emax (% WT)
cAMP Wildtype 9.84 ± 0.06 100 ± 2 8.70 ± 0.08 100 ± 3 10.7 ± 0.08 100 ± 2
R2.46176A 8.84 ± 0.09⁄ 92 ± 4 7.80 ± 0.10⁄ 85 ± 4⁄ 10.2 ± 0.09⁄ 99 ± 3
N2.52182A 9.09 ± 0.12⁄ 60 ± 3⁄ 7.37 ± 0.14⁄ 60 ± 4⁄ 9.49 ± 0.19⁄ 61 ± 4⁄
R3.30227A 8.38 ± 0.12⁄ 89 ± 5 7.35 ± 0.15⁄ 83 ± 6⁄ 9.70 ± 0.12⁄ 97 ± 1
Y3.53250A 9.51 ± 0.08 98 ± 3 8.35 ± 0.06 105 ± 3 9.89 ± 0.13⁄ 100 ± 4
K4.64288A 8.78 ± 0.38⁄ 26 ± 4⁄ 7.12 ± 0.23⁄ 36 ± 5⁄ 8.87 ± 0.17⁄ 40 ± 3⁄
R5.40310A 7.28 ± 0.09⁄ 89 ± 4 6.30 ± 0.08⁄ 93 ± 4 7.88 ± 0.19⁄ 90 ± 7
R5.56326A 9.90 ± 0.06 101 ± 2 8.37 ± 0.07 108 ± 3 10.6 ± 0.09 100 ± 4
K6.35346A 10.9 ± 0.11⁄ 102 ± 3 10.0 ± 0.08⁄ 108 ± 2 11.6 ± 0.13⁄ 103 ± 3
R6.37348A 9.74 ± 0.09 97 ± 3 8.52 ± 0.09 103 ± 3 10.5 ± 0.16 95 ± 4
K6.40351A 9.50 ± 0.14 98 ± 5 8.63 ± 0.07 98 ± 3 10.8 ± 0.08 99 ± 2
E7.63408A 9.70 ± 0.24 57 ± 5⁄ 8.17 ± 0.16⁄ 70 ± 4⁄ 10.3 ± 0.20 61 ± 4⁄
Q7.65410A 9.21 ± 0.13⁄ 100 ± 5 7.94 ± 0.06⁄ 98 ± 2 9.89 ± 0.15⁄ 100 ± 5
pERK1/2 Wildtype 8.65 ± 0.07 100 ± 2 7.95 ± 0.05 100 ± 2 8.88 ± 0.04 100 ± 1
R2.46176A 8.14 ± 0.12 64 ± 3⁄ 7.61 ± 0.14 77 ± 5 8.54 ± 0.25 69 ± 6⁄
N2.52182A 8.30 ± 0.51 41 ± 8⁄ 7.63 ± 0.36 66 ± 11⁄ 8.41 ± 0.13 92 ± 4
R3.30227A 8.20 ± 0.10 109 ± 4 7.46 ± 0.07 107 ± 3 8.57 ± 0.12 84 ± 4
Y3.53250A 8.80 ± 0.91 18 ± 5⁄ 7.53 ± 0.21 22 ± 2⁄ 8.58 ± 0.98 28 ± 9⁄
K4.64288A 7.61 ± 0.25 26 ± 3⁄ 7.54 ± 0.22 21 ± 3⁄ 7.85 ± 0.13 42 ± 2⁄
R5.40310A 8.03 ± 0.48 22 ± 4⁄ 6.81 ± 0.25⁄ 32 ± 5⁄ 7.80 ± 0.63 18 ± 5⁄
R5.56326A 7.91 ± 0.07 37 ± 1⁄ 7.34 ± 0.20 116 ± 4 8.95 ± 0.13 84 ± 4
K6.35346A 8.20 ± 0.07 188 ± 5⁄ 7.66 ± 0.10 194 ± 9⁄ 8.34 ± 0.07 177 ± 5⁄
R6.37348A 8.51 ± 0.08 103 ± 3 8.25 ± 0.09 105 ± 4 8.89 ± 0.11 102 ± 4
K6.40351A 9.08 ± 0.08 86 ± 3 7.14 ± 0.11 43 ± 3⁄ 8.92 ± 0.24 47 ± 4⁄
E7.63408A 8.71 ± 0.24 61 ± 5⁄ 8.99 ± 0.11⁄ 51 ± 2⁄ 9.14 ± 0.17 53 ± 3⁄
Q7.65410A 8.07 ± 0.43 59 ± 10⁄ 6.74 ± 0.59⁄ 39 ± 14⁄ 8.16 ± 0.49 51 ± 10⁄p[]
iCa2+ Wildtype 8.01 ± 0.09 100 ± 4 7.29 ± 0.11 100 ± 6 8.10 ± 0.06 100 ± 3
R2.46176A 7.25 ± 0.38 65 ± 12⁄ 7.36 ± 0.56 49 ± 14⁄ 7.48 ± 0.38 44 ± 8⁄
N2.52182A ND ND ND ND ND ND
R3.30227A 7.30 ± 0.20 96 ± 9 8.01 ± 0.22 87 ± 8 7.33 ± 0.19 87 ± 8
Y3.53250A ND ND ND ND ND ND
K4.64288A ND ND 7.06 ± 0.15 94 ± 8 ND ND
R5.40310A ND ND ND ND ND ND
R5.56326A 6.69 ± 0.27 76 ± 13 ND ND 7.84 ± 0.64 18 ± 5⁄
K6.35346A 8.06 ± 0.07 285 ± 8⁄ 6.90 ± 0.06 281 ± 10⁄ 8.16 ± 0.07 271 ± 8⁄
R6.37348A 6.90 ± 0.48 33 ± 8 6.92 ± 0.19 69 ± 9 7.86 ± 0.32 30 ± 3⁄
K6.40351A ND ND 7.01 ± 0.27 53 ± 11⁄ 7.10 ± 0.60 26 ± 8⁄
E7.63408A 7.34 ± 0.41 65 ± 13⁄ 7.11 ± 0.12 77 ± 5 7.46 ± 0.49 57 ± 12⁄
Q7.65410A ND ND⁄ 7.18 ± 0.29 82 ± 13 6.47 ± 0.58⁄ 34 ± 15⁄
76 D. Wootten et al. / Biochemical Pharmacology 118 (2016) 68–87Mutation of R5.40310 (R5.40310A) resulted in a receptor that was
very poorly expressed at the cell surface (<40% of wildtype),
whereas R3.30227A and K4.64288A were expressed at a similar level
to the wildtype receptor (Table 1). All three mutant receptors dis-
played amarked loss in affinity for peptide agonists (Fig. 6, Table 1).
This was greater for GLP-1 and exendin-4 at R3.30277A (18–19-
fold) and K4.64288A (59- and 30-fold, respectively), compared to
oxyntomodulin where a 4- and 9-fold loss of affinity was observed,
respectively. R5.40310A displayed a similar reduction in affinity for
all three agonists (8–17-fold). The binding of the antagonist,
exendin-4(9–39), was not altered at K4.64288A or R5.40310A com-
pared to wildtype, whereas a small, yet significant increase in
affinity was measured for R3.30227A (Table 1).
After correction for changes in expression, R3.30227A showed
similar efficacy for generation of cAMP production and pERK1/2
relative to wildtype for the three peptides (Fig. 6, Table 3). How-
ever, there was a small, yet significant increase in efficacy for
iCa2+ for oxyntomodulin that was not observed with the other
two peptide agonists. For R5.40310A, a small reduction in cAMP effi-
cacy was observed for GLP-1 and exendin-4, but not oxyntomod-
ulin. In addition, pERK1/2 efficacy was also slightly reduced for
exendin-4 and GLP-1 (3–5-fold), but not for oxyntomodulin
(Fig. 6, Table 3). In contrast, no detectable iCa2+ was evident forany peptide at R5.40310A. K4.64288A impaired cAMP efficacy for
all three peptides, but this was greater for GLP-1 and exendin-4
(42–50-fold) compared to oxyntomodulin (18-fold). In addition,
there was no detectable calcium response with GLP-1 and
exendin-4, although the oxyntomodulin efficacy for this pathway
was unaltered. In contrast, all three ligands displayed a similar
reduction in pERK1/2 efficacy (7–14-fold) (Fig. 6, Table 3).
Calculation of bias factors revealed that R5.40310 did not signif-
icantly alter the ability of the receptor to sample between distinct
conformations for activation of pERK1/2 and cAMP. Bias could not
be calculated relative to iCa2+, as there was no detectable response
for this pathway (Fig. 5, Table 5). K4.64288A biased the receptor
towards iCa2+ over cAMP and pERK1/2 when activated by oxynto-
modulin and for exendin-4 towards pERK1/2 relative to cAMP
(Fig. 5, Table 5). R3.30227 significantly biased GLP-1 towards iCa2+
over cAMP, with a similar trend for oxyntomodulin and exendin-
4 (Fig. 5, Table 5). This trend may not have been predicted from
efficacy values alone as, unlike the majority of mutants assessed
in this study, the functional KA values predicted from operational
modelling were also altered differentially in the distinct pathways
(Table 4). The functional KA linked to cAMP accumulation tracked
with the loss of affinity, however in iCa2+, little reduction in the
functional KA was observed compared to the wildtype receptor.
Table 4
Effects of mutation on the function KA derived from operational fitting to cAMP, pERK1/2 and iCa2+ mobilisation data. Mutant and WT GLP-1Rs were stably expressed in ChoFlpIn
cells and concentration-response curves were generated for each construct in each pathway for the three agonists. All data were analysed with an operational model of agonism
(Eq. 2) to determine LogKA (functional affinity) values. Values are expressed as mean ± S.E.M of four to six independent experiments, conducted in duplicate. ND means data were
unable to be experimentally defined.
Receptor construct Log KA
cAMP pERK1/2 iCa2+
GLP-1 Oxyntomodulin Exendin-4 GLP-1 Oxyntomodulin Exendin-4 GLP-1 Oxyntomodulin Exendin-4
Wildtype 8.35 ± 0.10 7.44 ± 0.09 9.24 ± 0.10 7.84 ± 0.11 7.46 ± 0.08 8.31 ± 0.07 7.32 ± 0.14 7.23 ± 0.34 7.46 ± 0.05
R2.46176A 8.08 ± 0.22 7.01 ± 0.10 8.95 ± 0.36 7.75 ± 0.14 7.39 ± 0.13 8.12 ± 0.09 7.26 ± 0.13 7.38 ± 0.04 7.39 ± 0.12
N2.52182A 8.50 ± 0.09 7.13 ± 0.13 9.16 ± 0.18 7.91 ± 0.13 7.40 ± 0.12 8.21 ± 0.12 ND ND ND
R3.30227A 7.50 ± 0.27 6.69 ± 0.22 8.13 ± 0.10 6.81 ± 0.06 6.81 ± 0.13 7.31 ± 0.05 6.79 ± 0.21 7.81 ± 0.24 6.82 ± 0.13
Y3.53250A 8.24 ± 0.10 7.23 ± 0.22 9.37 ± 0.10 7.70 ± 0.11 7.11 ± 0.08 8.11 ± 0.19 ND ND ND
K4.64288A 6.91 ± 0.32 6.29 ± 0.06 8.16 ± 0.23 7.13 ± 0.40 7.30 ± 0.38 7.01 ± 0.12 ND 6.90 ± 0.17 ND
R5.40310A 7.52 ± 0.35 6.07 ± 0.41 7.79 ± 0.30 7.91 ± 0.15 6.35 ± 0.35 7.53 ± 0.31 ND ND ND
R5.56326A 8.61 ± 0.13 7.56 ± 0.17 9.22 ± 0.13 7.83 ± 0.11 7.10 ± 0.28 8.33 ± 0.41 7.26 ± 0.17 ND 7.10 ± 0.19
K6.35346A 9.18 ± 0.19 7.64 ± 0.07 9.91 ± 0.11 8.32 ± 0.04 7.68 ± 0.03 8.21 ± 0.07 7.91 ± 0.15 7.27 ± 0.16 7.78 ± 0.08
R6.37348A 8.53 ± 0.21 7.43 ± 0.08 9.37 ± 0.10 7.73 ± 0.12 7.39 ± 0.17 8.35 ± 0.30 7.50 ± 0.14 7.01 ± 0.10 7.08 ± 0.09
K6.40351A 8.14 ± 0.23 7.48 ± 0.10 9.31 ± 0.09 7.80 ± 0.15 7.51 ± 0.19 8.12 ± 0.19 ND 7.40 ± 0.10 7.15 ± 0.21
E7.63408A 8.87 ± 0.18 7.11 ± 0.11 8.89 ± 0.18 7.81 ± 0.09 7.02 ± 0.19 8.35 ± 0.27 7.16 ± 0.21 6.91 ± 0.23 7.01 ± 0.09
Q7.65410A 8.01 ± 0.31 6.99 ± 0.33 9.41 ± 0.11 7.70 ± 0.18 7.33 ± 0.23 8.35 ± 0.27 ND 7.25 ± 0.15 7.10 ± 0.30
Table 3
Effects of mutation on GLP-1R coupling efficiency to downstream effectors, cAMP, pERK1/2 and iCa2+ mobilisation. Mutant and WT GLP-1Rs were stably expressed in ChoFlpIn
cells and concentration–response curves were generated for each construct in each pathway for the three agonists. All data were analysed with an operational model of agonism
to determine logs values that define efficacy. All logs values were corrected to cell surface expression data from the ELISA (logsc). Values are expressed as mean ± S.E.M of four to
six independent experiments, conducted in duplicate. Data were analysed with one-way analysis of variance and Dunnett’s post test (*p < 0.05). ND means data were unable to be
experimentally defined.
Receptor
construct
Log Tauc
cAMP pERK1/2 iCa2+
GLP-1 Oxyntomodulin Exendin-4 GLP-1 Oxyntomodulin Exendin-4 GLP-1 Oxyntomodulin Exendin-4
Wildtype 1.22 ± 0.09
(17)
0.92 ± 0.16
(8.4)
1.33 ± 0.15
(21)
0.08 ± 0.03
(0.83)
0.07 ± 0.03
(0.84)
0.09 ± 0.03
(0.81)
0.30 ± 0.04
(0.50)
0.31 ± 0.02
(0.49)
0.31 ± 0.03
(0.49)
R2.46176A 0.72 ± 0.21
(5.3)
0.49 ± 0.11
(3.1)
1.07 ± 0.07
(12)
0.29 ± 0.05
(0.52)
0.09 ± 0.06
(0.80)
0.28 ± 0.05
(0.52)
0.58 ± 0.12
(0.26)
0.40 ± 0.08
(0.40)
0.62 ± 0.13
(0.24)
N2.52182A 0.55 ± 0.07
(3.5)⁄
0.48 ± 0.07
(3.1)
0.55 ± 0.05
(3.6)⁄
0.39 ± 0.09
(0.41)
0.01 ± 0.09
(1.03)
0.20 ± 0.05
(1.58)
ND ND ND
R3.30227A 0.86 ± 0.17
(7.2)
0.53 ± 0.12
(3.3)
1.22 ± 0.10
(17)
0.02 ± 0.04
(1.05)
0.09 ± 0.06
(1.23)
0.22 ± 0.05
(0.61)
0.29 ± 0.07
(0.52)
0.08 ± 0.04
(1.20)⁄
0.34 ± 0.06
(0.46)
Y3.53250A 1.13 ± 0.29
(13)
0.93 ± 0.40
(8.5)
0.99 ± 0.20
(10)
1.23 ± 0.15
(0.06)⁄
1.12 ± 0.16
(0.08)⁄
1.16 ± 0.12
(0.07)⁄
ND ND ND
K4.64288A 0.47 ± 0.08
(0.34)⁄
0.32 ± 0.08
(0.48)⁄
0.28 ± 0.05
(0.5)⁄
1.11 ± 0.14
(0.08)⁄
1.22 ± 0.16
(0.06)⁄
0.96 ± 0.09
(0.11)⁄
ND 0.40 ± 0.05
(0.39)
ND
R5.40310A 0.67 ± 0.09
(4.7)⁄
0.76 ± 0.06
(5.8)
0.75 ± 0.06
(5.6)⁄
0.55 ± 0.15
(0.28)
0.27 ± 0.29
(0.54)
0.85 ± 0.21
(0.14)⁄
ND ND ND
R5.56326A 1.18 ± 0.10
(15)
0.91 ± 0.14
(8.0)
1.12 ± 0.13
(13)
1.01 ± 0.10
(0.10)⁄
0.07 ± 0.08
(0.85)
0.44 ± 0.06
(0.36)⁄
1.06 ± 0.17
(0.09)⁄
ND 1.09 ± 0.27
(0.08)⁄
K6.35346A 1.99 ± 0.10
(98)⁄
1.81 ± 0.24
(66)⁄
1.93 ± 0.37
(85)⁄
0.57 ± 0.09
(3.72)⁄
0.35 ± 0.06
(2.21)
0.68 ± 0.09
(4.74)⁄
0.50 ± 0.20
(3.2)⁄
0.32 ± 0.09
(2.1)⁄
1.12 ± 0.21
(13)⁄
R6.37348A 1.36 ± 0.19
(16)
1.37 ± 0.35 (23) 1.19 ± 0.12
(16)
0.12 ± 0.04
(1.32)
0.20 ± 0.06
(1.59)
0.13 ± 0.05
(1.33)
0.94 ± 0.21
(0.11)⁄
0.16 ± 0.08
(0.69)
0.86 ± 0.04
(0.14)⁄
K6.40351A 1.34 ± 0.10
(22)
0.95 ± 0.17
(9.0)
1.38 ± 0.19
(24)
0.15 ± 0.04
(0.71)
0.82 ± 0.16
(0.15)⁄
0.69 ± 0.08
(0.20)⁄
ND 0.47 ± 0.11
(0.34)
1.02 ± 0.22
(0.10)⁄
E7.63408A 0.44 ± 0.06
(2.8)⁄
0.58 ± 0.07
(3.8)
0.50 ± 0.05
(3.2)⁄
0.19 ± 0.05
(0.64)
0.28 ± 0.07
(0.52)
0.38 ± 0.05
(0.42)
0.23 ± 0.13
(0.59)
0.07 ± 0.06
(0.85)⁄
0.33 ± 0.10
(0.47)
Q7.65410A 0.97 ± 0.10
(9.3)
0.67 ± 0.07
(4.7)
0.96 ± 0.11
(9.2)
0.47 ± 0.07
(0.40)
0.70 ± 0.19
(0.20)⁄
0.58 ± 0.09
(0.26)⁄
ND 0.22 ± 0.05
(0.60)
1.19 ± 0.17
(0.07)⁄
D. Wootten et al. / Biochemical Pharmacology 118 (2016) 68–87 773.2. Three conserved positively charged residues residing near the
intracellular ends of TMs 5 and 6 contribute to conformational
transitions upon receptor activation
R5.56326 and K6.35346 reside towards the intracellular side of
TMs 5 and 6, respectively. In the inactive apo model, both of these
residues are predicted to hydrogen bond to regions in ICL2 thatmay
be required to stabilise ground state receptor interactions. Interest-
ingly, alanine mutation of either of these residues increased cell
surface expression (Fig. 8, Table 1). For K6.35346A, this was detect-
able by both antibody labelling (175% of wildtype) and whole cell
binding (159% of wildtype).While increased expressionwas detect-able at R5.56326A using antibody labelling (112% wildtype), there
was significantly enhanced expression when calculating Bmax
values from radioligand binding (141% of wildtype) (Table 1).
In our active, peptide bound molecular model R5.56326 and
K6.35346 are predicted to undergo a reorientation compared to
the apo model, with both residues pointing away from the bundle
(Fig. 8). An additional charged residue, K6.40351 in TM6 is also
located in an outward orientation relative to the bundle that is in
a distinct orientation in the active model relative to the apo (Fig. 8).
While mutation of R5.56326 to alanine did not alter affinity of
either of the peptide agonists or the antagonist exendin-4(9–39),
K6.35346A and K6.40351A both had small, yet significant selective
Table 5
Effects of GLP-1R mutation on signal pathway bias. Data were analysed using an operational model of agonism to estimate logsc/KA ratios. Changes in logsc/KA ratios with respect
to WT were calculated to provide a measure of the degree of stimulus bias exhibited by mutant receptors across the three pathways relative to that of the control receptor (WT).
Values are expressed as mean ± S.E.M of four to six independent experiments, conducted in duplicate. Data were analysed with one-way analysis of variance and Dunnett’s post
test (*p < 0.05). ND indicates data unable to be experimentally defined.
DlogRn relative to WT
pERK1/2-cAMP ERK-iCa2+ iCa2+-cAMP
GLP-1 Oxyntomodulin Exendin-4 GLP-1 Oxyntomodulin Exendin-4 GLP-1 Oxyntomodulin Exendin-4
Wildtype 0.00 ± 0.12
(1.0)
0.00 ± 0.07
(1.0)
0.00 ± 0.09
(1.0)
0.00 ± 0.11
(1.0)
0.00 ± 0.10
(1.0)
0.00 ± 0.10
(1.0)
0.00 ± 0.13
(1.0)
0.00 ± 0.15
(1.0)
0.00 ± 0.09
(1.0)
R2.46176A 0.29 ± 0.15
(1.9)
0.70 ± 0.15
(5.0)
0.37 ± 0.16
(2.3)
0.29 ± 0.29
(1.9)
0.24 ± 0.33
(0.57)
0.57 ± 0.31
(3.7)
0.57 ± 0.32
(3.7)
0.52 ± 0.33
(3.3)
0.21 ± 0.31
(0.62)
N2.52182A 0.31 ± 0.32
(2.0)
0.86 ± 0.21
(7.2)
0.99 ± 0.20
(9.8)⁄
ND ND ND ND ND ND
R3.30227A 0.52 ± 0.24
(3.3)
0.97 ± 0.12
(9.3)
0.25 ± 0.17
(1.8)
0.26 ± 0.17
(1.8)
1.06 ± 0.15
(0.09)⁄
0.24 ± 0.18
(1.7)
0.86 ± 0.26
(7.2)⁄
0.81 ± 0.17
(6.4)
0.52 ± 0.14
(3.3)
Y3.53250A 0.94 ± 0.39
(0.11)
1.13 ± 0.36
(0.07)⁄
0.44 ± 0.30
(0.36)
ND ND ND ND ND ND
K4.64288A 0.69 ± 0.32
(4.9)
0.68 ± 0.37
(4.8)
1.17 ± 0.12
(15)⁄
ND 0.80 ± 0.28
(0.16)
ND ND 1.17 ± 0.32
(15)⁄
ND
R5.40310A 1.04 ± 0.41
(11)
0.65 ± 0.33
(4.5)
0.96 ± 0.49
(9.1)
ND ND ND ND ND ND
R5.56326A 1.03 ± 0.23
(0.09)⁄
0.49 ± 0.16
(3.1)
0.02 ± 0.17
(0.95)
0.19 ± 0.35
(0.64)
ND 0.67 ± 0.57
(4.7)
0.83 ± 0.18
(0.15)⁄
ND 0.50 ± 0.35
(0.32)
K6.35346A 0.51 ± 0.26
(0.31)
0.65 ± 0.26
(0.22)
0.38 ± 0.11
(0.42)
0.56 ± 0.23
(0.34)
0.08 ± 0.24
(1.2)
0.82 ± 0.07
(0.15)
0.66 ± 0.13
(0.22)
1.54 ± 0.11
(0.03)⁄
0.37 ± 0.10
(2.3)
R6.37348A 0.16 ± 0.16
(0.69)
0.49 ± 0.13
(3.1)
0.49 ± 0.14
(3.1)
1.38 ± 0.36
(24)⁄
0.61 ± 0.24
(4.1)
0.84 ± 0.09
(6.9)
1.40 ± 0.25
(0.04)⁄
0.11 ± 0.23
(0.79)
0.25 ± 0.29
(0.56)
K6.40351A 0.19 ± 0.21
(0.65)
1.18 ± 0.28
(0.07)⁄
0.51 ± 0.24
(0.30)
ND 1.07 ± 0.18
(0.09)⁄
0.10 ± 0.24
(1.3)
ND 0.24 ± 0.29
(0.57)
1.08 ± 0.21
(0.08)⁄
E7.63408A 0.80 ± 0.27
(6.3)
0.36 ± 0.21
(2.3)
0.64 ± 0.22
(4.4)
0.15 ± 0.33
(1.4)
0.54 ± 0.27
(0.29)
0.30 ± 0.29
(0.50)
0.90 ± 0.15
(8.0)⁄
0.70 ± 0.24
(5.0)
0.88 ± 0.29
(7.7)
Q7.65410A 0.37 ± 0.10
(0.43)
0.48 ± 0.44
(0.33)
0.10 ± 0.25
(0.79)
ND 1.07 ± 0.48
(0.08)⁄
0.90 ± 0.54
(7.9)
ND 0.47 ± 0.18
(3.0)
1.24 ± 0.52
(0.06)⁄
Fig. 5. Effect of mutations on agonist bias of GLP-1R signalling pathways. Radial plots of agonist bias factors (DDs/KA, the ratio of the transduction coefficient for one pathway
vs another, each normalised to the values determined for the wildtype receptor) derived from an operational model of agonism (see ‘‘Section 2”) plotted for each receptor
variant. Values greater than 1 denote bias towards pathway 1, and values less than 1 denote bias towards pathway 2 relative to signalling at the wildtype receptor. Left,
pERK1/2 (pathway 1) vs cAMP (pathway 2); middle, pERK1/2 (pathway 1) vs iCa2+ mobilisation (pathway 2); right, iCa2+ mobilisation (pathway 1) vs cAMP (pathway 2). All
plots show the bias factors for the mutant receptors relative to the wildtype receptor for GLP-1 (blue), exendin-4 (salmon) and oxyntomodulin (green). Data points plotted as
circles indicate statistically significant bias relative to the wildtype receptor (WT highlighted by the black reference line), whereas data plotted as triangles (at a value of 100
or 100) indicate that no significant signal could be detected for a particular pathway and therefor a bias factor could not be calculated. These values at 100 indicate no
signalling in pathway 1 (therefore implied bias towards pathway 2), whereas +100 indicates no signalling in pathway 2 (therefore implied bias towards pathway 1). The
residues are highlighted in the colour relevant to the clustering (and relevant figure) in which they are discussed in the results section.
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GLP-1 and exendin-4 affinity, with oxyntomodulin displaying a
similar trend, however no effect was observed on the affinity ofthe antagonist. In contrast, K6.40351A did not alter the affinity of
the peptide agonists, but showed reduced affinity for exendin-4
(9–39) compared to the wildtype receptor (Table 1).
Fig. 6. Mutation of positively charged residues predicted to interact with ECL2 impairs agonist affinity and alters receptor signalling in a pathway dependent manner. (A)
Tops of TMs 2, 3, 4 and 5 of the apo GLP-1R TM bundle highlighting interactions between charged residues R3.30227, K4.64288, R5.40310 and residues located within ECL2
(R3.30227-D293, K4.64288-N304, R5.40310-N300). (B) TMs 2, 3, 4 and 5 of the GLP-1 docked activated GLP-1R TM bundle highlighting interactions between charged residues
R3.30227, K4.64288, R5.40310 and residues located within ECL2 (R3.30227-D293, K4.64288- E292/N304, R5.40310-N300). Also shown is the GLP-1 peptide (dark red) with T11 that
interacts directly with N300 located within ECL2. H7 of GLP-1 is also highlighted residing close to R5.40310. (C) Differences in equilibrium binding affinity (pKi) of mutant
receptors relative to wildtype for GLP-1, oxyntomodulin and exendin-4. (D–F) Differences in the coupling efficiency (logsc) of GLP-1, exendin-4 and oxyntomodulin to three
signalling pathways (cAMP production (D), pERK1/2 (E) and iCa2+ mobilisation (F)) at individual mutants compared to the wildtype receptor. These logsc were calculated from
concentration–response curves presented in Figs. 2–4, and corrected for cell surface expression as measured by antibody labelling recorded in Table 1. Statistical significance
of changes in affinity or coupling efficacy in comparison with wildtype were determined by one-way analysis of variance and Dunnett’s post test, and values are indicated
with an asterisk (⁄, p < 0.05). All values are ± S.E.M of four to six independent experiments, conducted in duplicate.
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three signalling pathways, although this did not reach statistical
significance for oxyntomodulin in pERK1/2 (Fig. 8, Table 3). While
GLP-1 and oxyntomodulin displayed a similar fold increase in effi-
cacy for calcium signalling (5–6-fold), there was a larger enhance-
ment for exendin-4 at this mutant (26-fold) (Fig. 8, Table 2).
Neither R5.56326A nor K6.40351A altered cAMP efficacy of any
ligand, but both had ligand-selective negative effects on pERK1/2.
R5.56326A reduced the efficacy of GLP-1 (8-fold) and to a lesser
extent exendin-4, with no effect on oxyntomodulin. In contrast,
K6.40351A reduced the efficacy of oxyntomodulin and exendin-4,with no effect on GLP-1. R5.56326A and K6.40351A also heavily
impaired iCa2+ when activated by GLP-1 and exendin-4, whereas
oxyntomodulin-mediated iCa2+ was impaired only at R5.56326A
(Fig. 8, Table 3).
The ability of these mutations to selectively alter efficacy of dis-
tinct pathways and/or ligands resulted in different bias profiles of
these mutant receptors relative to the wildtype (Table 5, Fig. 5).
K6.35346A altered the coupling preference induced by oxyntomod-
ulin, such that the receptor was even more strongly biased towards
cAMP relative to iCa2+ than wildtype, with a similar trend also seen
for GLP-1 (Table 5, Fig. 5). R5.56326A biased GLP-1 signalling
Fig. 7. R5.40310 forms transient interactions with His7 of GLP-1. Molecular dynamics simulation was performed for a total of 500 ns commencing with the final model of the
GLP-1 bound GLP-1R. (A) Interactions are identified between R5.40310 and both N300 and His7 throughout the first half of the simulation. However towards the end of the
simulation the interactions with both N300 and His7 are lost and R5.40310 forms a stable interaction with E6.53364. (B) Hydrogen bonds formed between R5.40310-His7 during
the 500 ns simulation. Hydrogen bonds were defined with the donor–acceptor distance < 3.0 Å and an angle cutoff of 20.
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not signal to iCa2+ at this mutant and therefore may be biased
towards pERK1/2 and cAMP over iCa2+ (Fig. 5, Table 5). Exendin-4
showed no significant change from wildtype at R5.56326A.
K6.40351A was biased away from iCa2+ towards both cAMP and
pERK1/2 when activated by GLP-1. Exendin-4 signaling also
showed a significant bias for cAMP relative to iCa2+. In contrast,
oxyntomodulin biased the signaling away from pERK1/2 relative
to cAMP and iCa2+ at this receptor in comparison to the wildtype
(Fig. 5, Table 5).
3.3. A hydrogen bond network at the intracellular face stabilises the
apo-GLP-1R and plays a role in controlling conformational transitions
linked to biased signalling
Molecular modelling of the GLP-1R revealed a network of resi-
dues residing at the intracellular face of the receptor involving resi-
dues in TM2 (R2.46176), TM6 (R6.37348) and TM7 (N7.61406 and
E7.63408). These are predicted to form an extensive hydrogen bond
network in the ground state apo model (Fig. 9) that is disrupted in
the active state model. We have previously reported the effects of
alanine mutation of N7.61406 that demonstrated little effect on
receptor expression, ligand binding, cAMP formation or iCa2+
([66], Fig. 9). However, there were small, yet significant reductions
in the ability of this mutant to promote pERK1/2 when activated by
GLP-1 and oxyntomodulin, but not exendin-4 (Fig. 9).
Mutation of R2.46176, R6.37348 or E7.63408 to alanine each
resulted in a significant loss of cell surface expression (Fig. 9,
Table 1). Interestingly, each mutation reduced this expression to
a similar extent (57–66% of wildtype), supporting the role of these
residues in a combined network. Despite this, relatively subtle
effects were observed on other aspects of receptor function. All
three mutants maintained the ability to bind the three agonists
and the antagonist, albeit that a small yet significant reduction
(4-fold) in exendin-4 affinity was observed for E7.63408A (Table 1).
In addition, subtle changes to receptor bias occurred that did not
always affect all three peptide ligands equally (Fig. 9, Tables 3and 5). E7.63408A reduced cAMP signalling by all peptides,
although this did not reach significance for oxyntomodulin
(Fig. 9, Table 3). This resulted in E7.63408A being biased towards
iCa2+ relative to cAMP for all ligands, but this only reached signifi-
cance for GLP-1 (Fig. 5, Table 5). R6.37348A selectively altered effec-
tor signalling, reducing iCa2+ for GLP-1 and exendin-4, but not
oxyntomodulin (Fig. 9, Table 3). This resulted in a statistically sig-
nificant switch in the receptor bias when activated by GLP-1, such
that it more readily activated effector coupling linked to pERK1/2
and cAMP compared to iCa2+ (Table 5, Fig. 5). R2.46176A had no sig-
nificant effect on efficacy relative to wildtype.
3.4. A conserved polar residue in H8 is selectively important for GLP-1
mediated signalling, with little impact on exendin-4 and
oxyntomodulin
Q7.65410A was assessed as part of this study as it is highly con-
served in class B GPCRs, but it is not located with the TM bundle,
rather at the start of the predicted helix 8 (H8) at the bottom of
TM7. In our apo model Q7.65410 is predicted to form a direct hydro-
gen bond with the backbone of TM7 (F7.59404) and with the side
chain of N7.62407 and therefore may stabilise the hinge region
between TM7 and H8 (Fig. 9). In the active model the interaction
with the backbone of TM7 is maintained, but the interaction with
N7.62407 is lost due to a reorientation of the bottom of TM7 upon
activation where N7.62407 then resides close to the Gas fragment
(Fig. 9). While mutation of Q7.65410 slightly reduced cell surface
expression, it had selective effects on GLP-1R efficacy, with no sig-
nificant effect on affinity of any ligand (Table 1). GLP-1 and
exendin-4 mediated cAMP formation and pERK1/2 were also unaf-
fected, however no iCa2+ could be detected when activated by GLP-
1 and there was also reduced exendin-4 efficacy for this pathway
(Fig. 9, Tables 1 and 3). This resulted in a significant bias of this
mutant receptor relative to the wildtype towards cAMP formation
compared to iCa2+ for exendin-4, and implies a similar bias for GLP-
1 (Fig. 5, Table 5). For oxyntomodulin a different profile was
observed; this ligand displayed reduced efficacy for pERK1/2 with
Fig. 8. Mutation of positively charged residues predicted to interact with ICL2 and/or the lipid bilayer alters cell surface expression and receptor signalling in a pathway
dependent manner. (A) TMs 3, 4, 5 and 6 of the apo GLP-1R TM bundle as viewed from the cytoplasmic face, highlighting interactions between charged residues R5.56326 and
K6.35346 with residues in ICL2. K6.40351 is also shown where it points away from the bundle, interacting with the backbone of ICL3 and potentially interacting with lipid head
groups. (B) The activated GLP-1R TM bundle as viewed from the intracellular face with a Gas peptide fragment docked at the cytoplasmic face. The lipid facing location of
R5.56326, K6.35346 and K6.40351 are highlighted. Of particular note, interactions of K6.35346 with ICL2 are broken to accommodate opening up of the TM bundle and G protein
interaction. R5.56326 interactions with the backbone of ICL2 are also broken although R5.56326 maintains within H bond proximity to Y252. (C) Cell surface expression of
mutations R5.56326A, K6.35346A and K6.40351A relative to the wildtype receptor as assessed by antibody binding to the N-terminal c-myc epitope tag. (D) Differences in the
coupling efficiency (logsc) of GLP-1, exendin-4 and oxyntomodulin to three signalling pathways (cAMP production (left), iCa2+ mobilisation (middle), and pERK1/2 (right)) for
R5.56326A, K6.35346A and K6.40351A compared to the wildtype receptor. These logsc were calculated from concentration–response curves presented in Figs. 2–4, and
corrected for cell surface expression as measured by antibody labelling recorded in Table 1. Statistical significance of changes in cell surface expression or coupling efficacy in
comparison with wildtype were determined by one-way analysis of variance and Dunnett’s post test, and values are indicated with an asterisk (⁄, p < 0.05). All values are ± S.E.
M of four to six independent experiments, conducted in duplicate.
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Q7.65410A towards iCa2+ relative to pERK1/2 compared to the wild-
type receptor (Figs. 5 and 9, Tables 3 and 5).
3.5. N2.52182 and Y3.53250 stabilise interactions between TMs 2, 3 and
4 important for GLP-1R stability and controlling conformational
transitions linked to specific activation of individual signalling
pathways
N2.52182 and Y3.53250 located in TMs 2 and 3, respectively, are
predicted to form interactions with residues V4.46270 (and poten-
tially W4.50274) and the backbone of Y4.45269, respectively, in
the apo receptor, all located in TM4. Our GLP-1 bound active recep-
tor model suggests a reordering of TM2 relative to TM3 and TM4
upon receptor activation resulting in formation of new interactions
by the side chain of N2.52182. In the active state, while this residue
remains close to TM4, it also interacts with Y2.48178 in TM2 and
W3.46243 in TM3 (Fig. 10).
While the TM3–TM4 interaction does not appear to be impor-
tant for receptor stability (as mutation of Y3.53250 had no effect
on receptor expression), the interaction of N2.52182 in TM2 with
TM4 residues may be important for receptor integrity as its muta-
tion to alanine heavily impaired cell surface expression (39% ofwildtype through antibody detection) (Table 1, Fig. 10). Due to this
heavily impaired expression, radioligand binding could not be
detected and therefore ligand affinities could not be assessed
(Table 1). Following correction for the loss in cell surface expres-
sion, pERK1/2 efficacy was not significantly altered at this muta-
tion, however cAMP production was impaired for GLP-1 and
exendin-4 (5–6-fold) and no iCa2+ could be detected for any of
the three peptides (Fig. 10, Tables 2 and 3). N2.52182A significantly
enhanced the coupling preference to pERK1/2 relative to cAMP for
exendin-4 only, although a similar trend was observed with oxyn-
tomodulin (Fig. 5, Table 5). The inability to detect an iCa2+ signal for
N2.52182A indicates that this receptor is likely biased towards
cAMP and pERK relative to iCa2+ for all ligands (Fig. 5, Table 5).
While mutation of Y3.53250 had little effect on receptor expres-
sion, agonist affinity or cAMP formation, pERK1/2 was impaired
(around 10-fold) and there was no detectable iCa2+ when activated
by all three agonist peptides (Fig. 10, Tables 1–3). Despite this, only
oxyntomodulin displayed significantly altered bias with bias
towards cAMP production relative to pERK1/2, but as there was
no detectable iCa2+ response for any peptide, it could be speculated
that this mutation may also alter the bias of the GLP-1R away from
iCa2+, towards cAMP and pERK1/2 for all peptide agonists (Fig. 5,
Table 5).
Fig. 9. Effects on mutation of residues located in the hydrogen bonding network located between TMs 2, 6 and 7 at the cytoplasmic face. (A) TMs 2, 6, 7 and helix 8 (H8) of the
apo GLP-1R TM bundle as viewed from the cytoplasmic face, highlighting an extensive hydrogen bond network between R2.46176, R6.37348, N7.61406 and E7.63408. Q7.65410 at
the start of H8 is also shown where it forms hydrogen binds with the side chain of N7.61407 and the backbone of TM7 at F7.59404. (B) TMs 2, 6, 7 and H8 of the GLP-1 docked
GLP-1R TM bundle as viewed from the cytoplasmic face with the Gas peptide fragment indicating the extensive hydrogen bond network between R2.46176, R6.37348, N7.61406
and E7.63408 is broken in the activated receptor. Q7.65410 at the start of H8 is also shown where it still maintains a backbone interaction with F7.59404. (C) Cell surface
expression of mutations R2.46176A, R6.37348A, N7.61406A, E7.63408A and Q7.65410A relative to the wildtype receptor (as assessed by antibody binding to the N-terminal c-myc
epitope tag). (D) Differences in the coupling efficiency (logsc) of GLP-1, exendin-4 and oxyntomodulin to three signalling pathways (cAMP production (top), iCa2+ mobilisation
(middle), and pERK1/2 (bottom)) for R2.46176A, R6.37348A, N7.61406A, E7.63408A and Q7.65410A compared to the wildtype receptor. These logsc were calculated from
concentration–response curves presented in Figs. 2–4, and corrected for cell surface expression as measured by antibody labelling recorded in Table 1. Statistical significance
of changes in cell surface expression or coupling efficacy in comparison with wildtype were determined by one-way analysis of variance and Dunnett’s post test, and values
are indicated with an asterisk (⁄, p < 0.05). All values are ±S.E.M of four to six independent experiments, conducted in duplicate.
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Class B GPCRs are activated through interaction of the
N-terminal region of their peptide agonists with the TM bundle of
the receptor [47,48,6,41]. ECL2 plays an important role in this acti-
vation process [23,30,63] and mutations within this domain in the
GLP-1R result in impaired cAMP production and iCa2+ with lessdramatic effects on pERK1/2 [30,31,65]. In addition, these muta-
tions within ECL2 altered the efficacy of the pERK1/2 biased agonist
oxyntomodulin differentially to GLP-1 and exendin-4 highlighting a
key role of this domain in biased agonism. Here, we reveal ligand-
dependent roles in peptide affinity and activation of the GLP-1R
of three highly conserved positively charged residues (R3.30227,
K4.64288 and R5.40310) that have previously been implicated in
Fig. 10. Effects on mutation of residues located TMs 2 and 3 that are predicted to intact with TM4. TMs 2, 3 and 4 of the apo GLP-1R TM bundle (A) and the activated GLP-1:
GLP-1:Gas peptide fragment (B) highlighting N2.52182 (red) and Y3.53250 (blue) and interacting residues within TM4 and TM3 (in the active model). (C) Cell surface expression
of mutations N2.52182A and Y3.53250A relative to the wildtype receptor (as assessed by antibody binding to the N-terminal c-myc epitope tag). (D) Differences in the coupling
efficiency (logsc) of GLP-1, exendin-4 and oxyntomodulin to cAMP production (left) and pERK1/2 right) for N2.52182A and Y3.53250A compared to the wildtype receptor.
These logsc were calculated from concentration–response curves presented in Figs. 2–4, and corrected for cell surface expression presented in (C). There was no detectable
signalling for either mutant in calcium mobilisation for any of the three peptides. Statistical significance of changes in cell surface expression or coupling efficacy in
comparison with wildtype were determined by one-way analysis of variance and Dunnett’s post test, and values are indicated with an asterisk (⁄, p < 0.05). All values are ±S.E.
M of four to six independent experiments, conducted in duplicate. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version
of this article.)
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molecular models to form stabilising interactions with ECL2. The
conservation of positively charged residues at positions 3.30 and
4.64 in all Class B GPCRs and the negative effect on receptor func-
tion that is observed following mutation in multiple Class B GPCRs
(Table 6) implies there may be a common role in stabilisation of
ECL2 by these residues for this class of receptors. The distinct effects
of mutation of R3.30227 and K4.64288 on affinity and efficacy of GLP-
1 and exendin-4 relative to oxyntomodulin are particularly inter-
esting as oxyntomodulin is a biased agonist relative to GLP-1 and
exendin-4. These observations were more prominent for K4.64288
and mutation of the proposed interacting residues in ECL2 (E292A
and N304A) also resulted in similar ligand-dependent changes
[30,31]. These data support a role for K4.64288 in controlling
activation transition leading to biased agonism by influencing the
conformation of ECL2 and its interaction with distinct agonists. A
recent study also predicted a similar interaction of K4.64288 with
ECL2, further supporting this theory [15]. Interestingly, for the
calcitonin-like receptor (CLR) where a receptor activity modifying
protein (RAMP) is required for function, mutation of R4.64 altered
adrenomedullin function at CLR-RAMP2 or CLR-RAMP3 complexes,but not CGRP function at CLR-RAMP1 [60,63]. This suggests that in
Class B receptor-RAMP complexes, stabilisation of ECL2 by R/K4.64
may have distinct functional consequences, in addition to control-
ling biased agonism of ligands acting at the same receptor.
R5.40310, also conserved as a positive charge in many Class B
GPCRs, interacts with ECL2 in our modelling, residing close to
N300 that is predicted to form a direct interaction with GLP-1
(Fig. 6). R5.40310 and N300 are both required for high affinity bind-
ing of GLP-1, exendin-4 and oxyntomodulin, with mutations of
each having similar effects on affinity and both affecting efficacy
of all three peptide agonists [30,31], therefore their proposed inter-
action may be important for peptide recognition. A polar residue at
5.40 is also required for function in other Class B GPCRs, particu-
larly those in the glucagon subfamily (Table 6). In contrast to this
proposed interaction of R5.40310 with N300, a recently published
study predicted a direct interaction of R5.40310 with His7 of GLP-
1 [15]. Although absent in our static active state model, these side
chains are in close proximity and in MD simulations (500 ns),
R5.40310 forms transient interactions with His7 of GLP-1 (Fig. 7).
Interestingly, for the GLP-1R, R5.40310 also plays a role in control-
ling biased agonism, with distinct negative effects upon mutation
Table 6
Published information for Class B GPCRs following mutation of the conserved polar residues assessed in this study. h, human; o, opossum; r, rat. GLP-1(R); glucagon-like peptide-1
(receptor); CLR, calcitonin-like receptor; RAMP, receptor activity modifying protein; CGRP, calcitonin gene related peptide; SecR, secretin receptor; PTH-(R), parathyroid hormone
(receptor); GCGR, glucagon receptor; VPAC-(R), vasoactive intestinal polypeptide (receptor); GIP(R), glucose-dependent insulinotropic peptide (receptor). CRE; cAMP response
element.
Position (Class B Wootten
numbering)
Mutant Receptor Effect compared with WT Reference
2.46 R2.46A hGLP-1R Decreased GLP-1 mediated cAMP potency [38]
R2.46A rGCGR No detectable cell surface expression [52]
R2.46A hCLR-
RAMP 1
Reduced CGRP mediated cAMP potency. [59]
R2.46A SecR Decreased secretin mediated calcium potency but not cAMP potency [17]
2.52 N2.52A hCLR-
RAMP1
No effect on CGRP affinity or cAMP production [59]
H2.52A oPTH-1R No effect on PTH-1 cAMP production. [57]
3.30 R3.30A rGLP-1R Reduced GLP-1 mediated cAMP production [69]
R3.30A hGCGR Reduced expression and glucagon affinity [15]
R3.30A rSecR Reduced secretin-mediated cAMP production [14]
K3.30A hCLR-
RAMP1
No effect on CGRP mediated cAMP production [59]
K3.30A hCLR-
RAMP2
Reduced adrenomedullin cAMP production [60]
K3.30A hCLR-
RAMP3
Reduced adrenomedullin cAMP production [60]
3.53 Y3.53A hVPAC1R Reduced VIP mediated cAMP production [55]
4.64 K4.64A rGLP-1R Reduced GLP-1 affinity [1]
K4.64A hGLP-1R Reduced expression, GLP-1 affinity and cAMP efficacy [15]
K4.64L hGCGR Reduced glucagon affinity [15]
R4.64A oPTH-1R No effect on PTH mediated cAMP [57]
R4.64A rSecR Decreased secretin mediated cAMP potency. [14]
R4.64A hCLR-
RAMP1
Reduced CGRP mediated cAMP pEC50. [59]
R4.64A hCLR-
RAMP2
Reduced adrenomedullin mediated cAMP production [60]
R4.64A hCLR-
RAMP3
Reduced adrenomedullin mediated cAMP production [60]
5.40 R5.40A hGLP-1R Reduced expression, GLP-1 affinity and GLP-1 mediated cAMP potency. [12]
R5.40A hGLP-1R Reduced expression, GLP-1 affinity and cAMP efficacy. [15]
R5.40A hGCGR Reduced expression and glucagon affinity [15]
R5.40A hGIPR Reduced GIP mediated cAMP production. [71]
H5.40A hCLR-
RAMP1
Reduced CGRP-mediated cAMP pEC50 [59]
5.56 N5.56A hCLR-
RAMP1
No effect on CGRP cAMP mediated production [59]
6.35 Y6.35A hVPAC1R No effect on VIP mediated cAMP [13]
6.37 K6.37A hCLR-
RAMP1
No effect on CGRP mediated cAMP production [10]
R6.37A hVPAC1R No effect on VIP mediated cAMP production [13]
R6.37A hSecR No effect on secretin mediated cAMP production [8]
R6.37G rGLP-1R Decreased GLP-1 affinity [20]
R6.37A rGLP-1R No effect on GLP-1 mediated cAMP production [54]
R6.37A rGCGR Enhanced glucagon mediated CRE reporter activity (potency and Emax) [52]
R6.37A hVPAC2R Reduced VIP mediated cAMP potency [35]
K6.37A hCRF-1R Increased CRF mediated cAMP potency (Gs), reduced pERK1/2 (Gi) [44]
6.37/6.40 R6.37A/
K6.40A
hSecR Reduced secretin mediated cAMP and calcium, no effect on affinity or receptor expression [17]
6.40 R6.40A hCLR-
RAMP1
5-fold reduction in CGRP affinity, 30-fold reduction in CGRP mediated cAMP production [10]
R6.40A hVPAC1R Reduced VIP mediated IP3 production, no effect on cAMP [36]
K6.40A rGLP-1R No effect on GLP-1 mediated cAMP production [54]
R6.40A hVPAC2R Reduced VIP mediated cAMP potency [35]
K6.40A hCRF-1R Increased urocortin mediated cAMP (Gs), reduced IP3 (Gq) [44]
7.61 N7.61A hGLP-1R No effect on expression, affinity, cAMP or calcium mobilisation, but reduced GLP-1 and
oxyntomodulin mediated pERK1/2 (not exendin-4)
[66]
N7.61A rGCGR Enhanced potency in glucagon mediated CRE reporter activity assay [52]
7.63 E7.63A hCLR-
RAMP1
Reduced CGRP-mediated cAMP potency [59]
E7.63A rGCGR Enhanced basal activity and enhanced potency in glucagon mediated CRE reporter activity
assay
[52]
E7.63 K oPTH-1R No effect on PTH mediated cAMP [57]
E7.63A hVPAC1R Decreased VIP mediated cAMP production [13]
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ulin. Interestingly, towards the end of our 500 ns MD simulation on
the GLP-1:GLP-1R model, transient interactions of R5.40310 with
His7 of GLP-1 and with N300 in ECL2 are lost and R5.40310, as wellas His7 of GLP-1 form stable interactions with E6.53364 (Fig. 6); part
of a key, central, hydrogen bond network that is critical for control-
ling GLP-1R biased agonism [64–66]. The mutational effect of
R5.40310 on GLP-1 and exendin-4 mediated signalling relative to
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residing in this central hydrogen bond network [64,65]; and sug-
gests distinct functional requirements of R5.40310, in combination
with the central hydrogen bond network for controlling peptide-
mediated GLP-1R activation leading to biased agonism. These MD
simulations with GLP-1 also suggest R5.40310 and N300 are key
residues in guiding the N-terminus of these peptide agonists into
the TM cavity for receptor activation (Fig. 7).
We have also previously reported on a key hydrogen bond net-
work located at the cytoplasmic side of the TM bundle, between
TMs 2, 3 and 6 that is essential for receptor integrity and for global
activation of the GLP-1R [64,66]. The current study reveals the
importance of an additional hydrogen bond network, also at the
intracellular face, formed by residues in TM2 (R2.46176), TM6
(R6.37348) and TM7 (N7.61408 and E7.63408) that is evident in the
crystal structures of the GCGR and CRF1R [22,49]. Differences in
our apo models vs GLP-1 peptide bound models suggest a reorgan-
isation of these intracellular networks involving a disruption of
crucial contacts between TMs 3 and 6, and TMs 2 and 7 result in
the TM bundle opening at the intracellular face, allowing for effec-
tor coupling. Mutation of these residues in both networks (with the
exception of N7.61406) significantly reduced cell surface expression
highlighting a role for both networks in receptor stability ([66],
Fig. 9). The role of these networks are also consistent with experi-
mental data from other Class B GPCRs where mutation of residues
either induced constitutive cAMP activity, enhanced potency for
cAMP production or result in poor receptor expression at the cell
surface, observations that are all consistent with destabilisation
of the inactive state [59], (Table 6). These combined data across
Class B GPCRs, in addition to the conservation of these interactions
in the two solved inactive state Class B GPCR TM crystal structures
support a common role for hydrogen bond networks at the cyto-
plasmic face in stabilisation of the apo receptor [22,49].
Residues within the newly reported TM2-6-7 network in the
GLP-1R also have independent roles for signal transduction after
being released from their ground state constraints. While we did
not identify a role for R2.46176 in transmission of efficacy, it may
play a minor role, as observed in a mutational study at the rat
GLP-1R (Table 6). In contrast, we revealed distinct roles for
R6.37348 and E7.63408 in directing signalling specificity. Consistent
with other Class B GPCRs (Table 6), E7.63408 selectively couples the
GLP-1R to cAMP (Gas). In contrast, R6.37348 plays a role in coupling
the GLP-1R to iCa2+ that is non-Gas-mediated [65], but only when
the receptor was activated by GLP-1 and exendin-4. Along with
R6.37348, K6.40351 forms part of a basic-X-X-basic motif (BxxB) that
is highly conserved in both Class A and B GPCRs, but the effects of
mutation are variable depending on the receptor being studied.
Evidence suggest residues in this motif play only minor roles in
Gas/cAMP efficacy for Class B GPCRs, but are more important for
IP3/calcium mobilisation (Table 6). This is consistent with this cur-
rent study on the GLP-1R, where mutation of both basic residues
had little effect on cAMP production by any peptide, but reduced
the efficacy of GLP-1 and exendin-4 for iCa2+. However, there was
no alteration in oxyntomodulin efficacy, consistent with distinct
receptor conformational propagation achieved by the ligand that
exposes distinct side chains for effector interaction. Therefore,
the BxxB motif may have distinct roles in controlling receptor con-
formation and effector coupling between ligands acting at the
same receptor. The observed effects of mutation of R6.37348,
K6.40351 and E7.63408 for signalling specificity could arise due to
direct contacts with effector proteins or indirectly through forming
interactions (either within the receptor or with lipids) that sta-
bilise active receptor conformations required for coupling to dis-
tinct pathways. Indeed, R6.37348 and E7.63408 are in the vicinity
of Gas in the GLP-1 boundmolecular model and therefore relatively
small differences in conformational rearrangement upon bindingof distinct agonists could subtly alter interactions with effector
proteins giving rise to the observed changes in signal bias.
Lys and Arg residues found near the polar/a-polar interfaces can
hydrogen bond to phosphate head groups and esterified oxygens of
the lipid backbone, anchoring TMs in the bilayer in the optimal ori-
entation in the membrane for receptor function [51]. From our
GLP-1R models, three residues R5.56326, K6.35346 and K6.40351
may play such a role as our active state model places these resi-
dues pointing out towards lipid. The reorientation of these three
side chains between the two models suggests that these residues
may be important for controlling TM movements during activation
transition. Mutation of R5.56326 and K6.35346 also increased cell
surface expression, an effect that is often associated with stabilisa-
tion of the ground state conformation. Indeed, Ala mutation of an
equivalent residue, Y6.35, in the CRF1R TM domain crystal struc-
ture was used to increase the thermostability of the inactive recep-
tor protein and to aid in crystallisation [22]. R5.56326A also
selectively impaired pERK1/2 by GLP-1 and exendin-4 and heavily
impaired iCa2+ by all ligands, consistent with stabilisation of an
inactive receptor. In contrast, K6.35346A enhanced affinity and sig-
nalling efficacy by all ligands to all three pathways. This residue is
only positively charged in the glucagon subfamily of Class B GPCRs
(being a polar Tyr in most others (Fig. 1)), and therefore may play a
different role in this glucagon subclass compared to the other Class
B members.
TM4 is the most peripherally located TM and forms the inter-
face for GLP-1R homodimerisation in Class B GPCRs that is impor-
tant for GLP-1R signalling [18]. N2.52182 and Y3.53250 pack up
against TM4 and play global roles in GLP-1R activation by peptide
agonists, with both residues being crucial for iCa2+ mobilisation,
but selectively involved in cAMP (N2.52182) or pERK signalling
(Y3.53250), effects that may arise due to stabilisation of the impor-
tant dimerisation interface. Consistent with this, mutation of either
residue had the largest impact on calcium signalling, which paral-
lels with the greater loss of calcium signalling relative to cAMP and
pERK1/2 following mutation of the TM4 dimerisation interface
within the GLP-1R [18]. Molecular modelling also predicts a
reordering of TM2 relative to TM3 and TM4 that may stabilise resi-
dues within TM3 in the activated receptor, a key domain for signal
transduction that may also contribute to the altered signalling at
these mutant receptors compared to the wildtype.
Collectively, this work expands our understanding of how pep-
tides activate the GLP-1R receptor to promote signalling, highlight-
ing additional key conserved Class B GPCR polar side chains within
the TM domain beyond those already reported. There is now a
large body of evidence from multiple Class B GPCRs that shed light
on how these complex receptors are activated with conserved
polar residues playing a crucial role in this process (Table 6
[68,66,64,65,59,9]. Despite their distinct mode of ligand interaction
relative to Class A GPCRs, there are some parallels in how these
two classes of receptors are activated. There is now substantial evi-
dence that ECL2 plays a major role in the binding and activation of
both classes of receptors [30,63,11,62]. However, conformational
differences within ECL2 have been identified, even within the Class
A subfamily [62], suggesting different networks of interactions are
involved in stabilisation of this important domain. In addition,
despite different conserved amino acids in the two subclasses,
polar interactions are crucial for signal propagation, facilitating
conformational TM rearrangements through the reorganisation of
hydrogen bond networks in Class A and Class B GPCRs
[2,3,42,66,64,9,59]. For Class A GPCRs, there is substantial evidence
that this results in a large-scale conformational transition of TM6
relative to TM3 that requires the disruption of key polar networks
at the intracellular face [46,45]. Limited evidence supports a simi-
lar movement of TM6 relative to TM3 in Class B GPCRs [50]. This
study, taken together with our previous studies [66,64], suggest
86 D. Wootten et al. / Biochemical Pharmacology 118 (2016) 68–87that breaking of key polar networks at the intracellular face of
Class B GPCRs (TM2-TM3-TM6 and TM2-TM6-TM7), like Class A
GPCRs, are crucial in this subfamily of receptors to facilitate move-
ments within TM6 allowing for effector interaction.
Additionally, there is an increasing body of evidence from
mutational studies supporting distinct modes of receptor activa-
tion by biased peptides at the GLP-1R, with this study providing
additional evidence for the role of polar interaction networks in
influencing how these differences may be achieved. There is also
evidence that the ability of individual ligands to influence polar
interactions within Class A GPCRs contributes to biased agonism
[53,70]. While our mutagenesis studies combined with GLP-1R
models can be used to facilitate understanding of mechanisms
for activation of Class B GPCRs and propagation of biased sig-
nalling, additional and more complex structural and biophysical
analysis of this receptor, (or any Class B GPCR) are required to gain
an in depth understanding of the large scale conformational move-
ments that allow these very complex receptor-ligand systems to
transmit signals from the ligand binding pocket at the extracellular
face to cytoplasmic signalling molecules.
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